Full-Time
Associate Data Engineer 1
Posted on 6/16/2026
AbbVie
10,001+ employees
Global biopharmaceutical company developing medicines
Compensation Overview
$58.7k - $103.5k/yr
Vernon Hills, IL, USA
Hybrid
 Data & Analytics (1) |
|---|
- Bachelor’s degree in computer science, data science or relevant field.
- Programming skills in Java, Python, R, or SQL.
- Prior exposure to data engineering.
- Design and develop data solutions to address business challenges.
- Demonstrate knowledge across a range of technologies related to programming languages, data integration, data warehousing, and data visualization and analysis.
- Responsible for building, maintaining, and optimizing data infrastructure.
- Ensure data is collected, processed, and stored efficiently and securely.
- Integrate different data sources and create the foundations on which analytics and data science can operate.
- Understand the broad objectives of projects as well as position's role in achieving objectives; modify approach when required.
- Escalates issues to ensure execution success and keeps stakeholders informed through effective verbal and written communication.
- Learn, understand and master new methods and technologies, and act as a resource or mentor for others.
- Produces and maintains required technical documentation associated with work products.
- Adhere to corporate standards regarding applicable Corporate and Divisional Policies, including code of conduct, safety, GxP compliance, data security, and the software development lifecycle.
- Experience interacting with APIs to extract data.
- Hands-on experience using large language models and machine learning algorithms.
- Demonstrated experience applying AI/ML in clinical or pharmaceutical contexts.
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Your Connections
People at AbbVie who can refer or advise you
Simplify's Take
What believers are saying
- The Durham campus investment adds manufacturing capacity and 734 new jobs.
- AQUIPTA's EU acute-migraine approval extends lifecycle value in headache care.
- Oncology momentum and CLL data support a growing non-immunology revenue base.
What critics are saying
- High leverage and negative equity constrain flexibility if growth slows.
- Patent-cliff pressure after 2028 leaves Skyrizi and Rinvoq carrying too much risk.
- Aesthetic and acquired-asset integration execution can disappoint and dilute returns.
What makes AbbVie unique
- AbbVie combines blockbuster immunology with consumer aesthetics, diversifying revenue streams.
- Skyrizi and Rinvoq have replaced Humira with rapid post-exclusivity growth.
- A partnered-pipeline model expands oncology and neuroscience without fully funding early discovery.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Flexible Work Hours
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%AbbVie is reportedly nearing an acquisition of Apogee Therapeutics, a biotechnology company developing therapies for inflammatory and immune diseases. Founded in 2022, Apogee recently secured financing of up to $1.3 billion from Blackstone Life Sciences last month to fund late-stage development and potential commercialisation of an eczema medication. No further details about the potential deal's terms or valuation have been disclosed.
AbbVie adds new location in Right to Work North Carolina. AbbVie is planning to establish operations in Right to Work Durham, North Carolina. The $1.4 billion investment is expected to create 734 new jobs for the community. Exciting! From Area Development Magazine: "Our investment in North Carolina represents a significant milestone for AbbVie as our largest capital investment to date and an important expansion of our manufacturing footprint into a new region of the United States. [...] By establishing this campus, we are strengthening our ability to support future medical breakthroughs while also creating new jobs and a long-term partnership with Durham and the State of North Carolina." [...] "This decision further cements North Carolina's position at the forefront of the global life sciences industry. [...] As our pharmaceutical sector grows, we remain fully committed to cultivating the highly skilled workforce, infrastructure, and ecosystem needed to deliver lifesaving medicines to patients around the world for companies like AbbVie." [...] "We are thrilled to welcome this significant investment, which serves as a powerful testament to Durham's growing reputation as a premier global hub for innovation and talent. [...] Beyond the economic impact, this partnership highlights the company's deep-rooted commitment to our community through sustainable growth and meaningful local engagement. Their decision to call Durham home reinforces our shared vision of a thriving, inclusive economy where corporate success and community prosperity go hand in hand." [...] "With continuous reinvestment in its training infrastructure, North Carolina remains eager to expand upon its strengths in biomanufacturing. [...] We are thrilled that AbbVie has selected Durham County and look forward to partnering to support the success of their North Carolina team." [...] "We're incredibly grateful that AbbVie chose Durham, bringing more than 700 high-quality jobs with six-figure average salaries. This is what real economic mobility looks like - creating pathways into the life sciences industry for more of our residents. [...] This win reflects what makes Durham special - strong partnership with the County, the Chamber, and coordinated execution across every City department, and we're proud to welcome AbbVie as a long-term community partner committed to our future." AREA DEVELOPMENT MAGAZINE
Haisco Pharma hands novel pain compound portfolio to AbbVie for USD 745m. April 13, 2026 A portfolio of novel pain compounds developed by Haisco Pharmaceutical Group (SZSE: 002653) has been licensed exclusively to AbbVie (NYSE: ABBV) under an agreement announced April 10, 2026. The deal grants AbbVie rights to develop, manufacture, and commercialize the compounds globally, excluding mainland China, Hong Kong, and Macau. The program covers multiple compounds at stages ranging from preclinical to Phase I in China, all targeting pain-related indications. Under the terms, Haisco receives a USD 30 million upfront payment and is eligible for up to USD 715 million in aggregate development, regulatory, and commercial milestones, bringing the total potential deal value to USD 745 million. Haisco is also eligible for tiered royalties on future net sales. Specific milestone triggers and royalty rates were not disclosed. Deal context. The compounds involved are described by Haisco as novel medicines for pain, but the press release does not identify specific molecule names, biological targets, or mechanisms of action. Haisco is known to be pursuing fast-follower NaV1.8 programs - targeting a voltage-gated sodium channel expressed in peripheral sensory neurons that plays a key role in pain signal transmission - following the approval of Vertex Pharmaceuticals' suzetrigine (Journavx) in January 2025. The Chinese firm has secured patents describing VX-548-derived scaffolds incorporating bioisosteric substitutions to modify the core structure. AbbVie has identified neuroscience as a core therapeutic focus alongside its established positions in immunology and oncology. However, the company has had limited recent deal activity specifically in pain, suggesting the Haisco transaction may represent an effort to expand its position in this segment within a broader neuroscience strategy. Other deals of note in the neuroscience space include the USD 8.7 billion acquisition of Cerevel Therapeutics in 2023, focused on later-stage CNS assets for schizophrenia, Parkinson's, and epilepsy. The deal also represents the latest collaboration between AbbVie with China-based partners. In January 2026, AbbVie struck a deal worth in excess of USD 5 billion with Remegen for a PD-1/VEGF bispecific antibody, while two separate partnerships were signed in 2025, with Zelgen Biopharmaceuticals for T-cell engagers, and Simcere Pharma for a trispecific antibody. For Haisco, the deal represents an extension of an international out-licensing strategy the company has pursued since 2015. Other notable partners include US based biotech AirNexis, which signed a deal worth in excess of USD 1 billion in January 2026 for PDE/4 respiratory asset of Haisco, HSK39004 The Chengdu-based company has R&D operations in Shanghai and Silicon Valley and has previously pursued international expansion through out-licensing, co-development, and acquisitions. Previous multinational partners include US biotech AirNexis and Italy's Chiesi Farmaceutici SpA. Your email address will not be published. Required fields are marked *
Haisco pharmaceuticals enters exclusive licensing agreement with AbbVie for pain medicines development. Monday, Apr 13, 2026 2:26 am ET 1min read Haisco Pharmaceutical Group has entered into an exclusive licensing agreement with AbbVie to develop novel medicines for pain treatment globally, excluding mainland China, Hong Kong, and Macau. The program includes multiple compounds at various development stages. Haisco will receive a $30 million upfront payment and up to $715 million in milestone payments, plus royalties on future net sales. The collaboration is expected to generate sustainable value and long-term returns. Haisco Pharmaceutical Group has entered into an exclusive licensing agreement with AbbVie to develop and commercialize two Nav1.8 inhibitors for pain treatment outside of mainland China, Hong Kong, and Macau. The compounds, HSK55718 and HSK51155, are intended for the development of non-opioid analgesics and are at different stages of clinical development. HSK55718 is in Phase I clinical trials in China as an intravenous therapy, while HSK51155 is in the preclinical stage as an oral formulation according to the announcement. Under the terms of the agreement, Haisco will receive a $30 million upfront payment and is eligible for up to $715 million in milestone payments, in addition to royalties on future net sales. AbbVie will also cover certain research and development costs through the proof-of-concept phase. The deal is expected to support Haisco's global expansion and enhance its long-term profitability. The collaboration aligns with Haisco's strategy to advance its innovative drug portfolio and strengthen its international commercialization efforts. Ask Aime: What are the potential impacts of Haisco's licensing deal with AbbVie on its stock performance? Aime insights. What's the performance trend of major Indian companies listed on US stock exchanges? Between Microsoft and Google, which is better for long-term holding? How to evaluate a company's competitive advantage? How does R&D spending compare among semiconductor leaders over years?
AbbVie showcases late-breaking phase 2 data for mirvetuximab soravtansine-gynx (ELAHERE(R) in platinum-sensitive ovarian cancer (PSOC) at SGO 2026.